RE:Looks like it has bottomed
It seems that Malhotra is not along. Following a slow of ratings after earnings, 7 analysts remain bullish on Valeant, 3 are bearish, and 10 are neutral. The average 12-month price target between these 20 analysts is $66.27, marking a 120% potential upside from current levels. Malhotra has a 41% success rate recommending stocks with a 7% average one-year loss per rating.
https://www.smarteranalyst.com/2016/03/18/earnings-roundup-embattled-valeant-pharmaceuticals-intl-inc-nysevrx-and-mannkind-corporation-nasdaqmnkd-struggle-to-regain-public-favor/